Clinical Trial Update: Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

View source ↗

Summary

A real-world study evaluating trastuzumab-deruxtecan in triple-negative metastatic HER2-low breast cancer conducted in Brazil has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: TERMINATED